Herbert Raymond McMaster
Known title: DirectorCIK: 0001811490
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Ono Pharmaceutical Rallies 13.9% Amid NRX Partnership. Ono Pharmaceutical shares rose 13.9%, a move likely tied to its ongoing relationship with NRX Pharmaceuticals. This partner's stock performance often influences sentiment around NRX, which is currently trading near its 52-week low. The significant gain in the partner's stock highlights the continued relevance of their collaboration in the market.
Transaction History
| ZM | ▼ Sell | Open Market | 5 | $444 | 7/14/2026 | View on chart |
| ZM | ▲ Buy | Option Exercise | 3,583 | $0 | 6/10/2026 | View on chart |
| ZM | ▼ Sell | Open Market | 2,000 | $166K | 8/25/2025 | View on chart |
| ZM | ▼ Sell | Open Market | 1,000 | $80K | 8/22/2025 | View on chart |
| ZM | ▼ Sell | Open Market | 500 | $38K | 7/14/2025 | View on chart |
| ZM | ▲ Buy | Option Exercise | 4,361 | $0 | 6/11/2025 | View on chart |
| ZM | ▲ Buy | Option Exercise | 4,089 | $0 | 6/12/2024 | View on chart |
| ZM | ▲ Buy | Option Exercise | 237 | $0 | 6/14/2023 | View on chart |
| ZM | ▲ Buy | Option Exercise | 236 | $0 | 3/18/2023 | View on chart |
| ZM | ▲ Buy | Option Exercise | 236 | $0 | 12/18/2022 | View on chart |
| ZM | ▲ Buy | Option Exercise | 236 | $0 | 9/18/2022 | View on chart |
| ZM | ▲ Buy | Option Exercise | 236 | $0 | 6/18/2022 | View on chart |
| ZM | ▲ Buy | Option Exercise | 236 | $0 | 3/18/2022 | View on chart |
| ZM | ▲ Buy | Option Exercise | 236 | $0 | 12/18/2021 | View on chart |
| ZM | ▲ Buy | Option Exercise | 236 | $0 | 9/18/2021 | View on chart |
| NRXP | ▲ Buy | Option Exercise | 18,300 | $41K | 8/26/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Zoom Stock: Analysts Note AI Growth Potential Amid Market Dip
Recent commentary highlights Zoom's high cash yield and potential for AI-driven growth, though some analysts remain cautious. The stock has recently dipped more than the broader market, trading near its 52-week low. With a low P/E ratio of 7.8, the company is seen as a cash-heavy name, but investors are watching for signs of a turnaround.
Zoom Stock: Analysts Note AI Growth Potential Amid Market Dip. Recent commentary highlights Zoom's high cash yield and potential for AI-driven growth, though some analysts remain cautious. The stock has recently dipped more than the broader market, trading near its 52-week low. With a low P/E ratio of 7.8, the company is seen as a cash-heavy name, but investors are watching for signs of a turnaround.